Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 4/2014

01-04-2014 | Oncology

Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma

Authors: Noriyasu Hashida, Kei Nakai, Norimitsu Saitoh, Kohji Nishida

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 4/2014

Login to get access

Abstract

Purpose

To investigate if the site of ocular lesions and prophylactic treatment in patients with primary vitreoretinal lymphoma (PVRL) are associated with the time to onset of central nervous system (CNS) involvement.

Methods

We retrospectively studied 26 patients (seven men, 19 women; mean age, 67.0 ± 11.1 years) with a diagnosis of PVRL at our hospital between January 2001 and October 2011 and a minimum 2-year follow-up after treatment. We classified the PVRL lesions as: (1) the vitreous opacity type, vitreous opacity of 2+ or higher without retinal lesions, (2) the retina type, vitreous opacity of 1+ or less with retinal lesions only, or (3) the concomitant type, with both. We also evaluated whether prophylactic treatment of systemic chemotherapy such as high-dose methotrexate (HD-MTX) and intrathecal MTX (IT-MTX), or topical ocular treatments such as intravitreal injections of MTX and rituximab, inhibited the onset of CNS involvement in patients with PVRL without cerebral involvement.

Results

During a mean follow-up of 44.0 ± 18.7 months, CNS involvement began in 14 patients (53.8 %), i.e., three (60 %) of five patients with retina-type lesions, five (41.7 %) of 12 patients with vitreous opacity-type lesions, and six (66.7 %) of nine patients with concomitant-type lesions. There was no significant (P = 0.496) association between the site of the ocular lesions and the onset of brain lesions. In addition, CNS involvement occurred in eight of 11 patients receiving CNS prophylactic chemotherapy and six of 15 patients receiving no prophylaxis; the difference between the two did not reach significance (P = 0.131). The time to onset of cerebral involvement in the CNS prophylactic chemotherapy group (42.8 ± 13.8 months) was significantly (P = 0.0005) longer than in the group that did not receive prophylaxis (10.2 ± 2.0 months). Preventive systemic chemotherapy, especially HD-MTX, significantly prolonged the time to the onset of brain lesions compared to IT-MTX and local ocular therapy.

Conclusions

While prophylactic systemic chemotherapy did not inhibit the onset of CNS involvement in most of patients with PVRL, it significantly prolonged the time to cerebral involvement.
Literature
3.
go back to reference Coupland SE, Heimann H, Bechrakis NE (2004) Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 242:901–913PubMedCrossRef Coupland SE, Heimann H, Bechrakis NE (2004) Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 242:901–913PubMedCrossRef
4.
5.
6.
go back to reference Peterson K, Gordon KB, Heinemann MH, DeAngelis LM (1993) The clinical spectrum of ocular lymphoma. Cancer 72:843–849PubMedCrossRef Peterson K, Gordon KB, Heinemann MH, DeAngelis LM (1993) The clinical spectrum of ocular lymphoma. Cancer 72:843–849PubMedCrossRef
7.
go back to reference Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Miléa D, Gerber S, Fardeau C, Reux I, Xuan KH, Chan CC, LeHoang P (2000) Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 8:243–250PubMedCrossRef Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Miléa D, Gerber S, Fardeau C, Reux I, Xuan KH, Chan CC, LeHoang P (2000) Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 8:243–250PubMedCrossRef
8.
go back to reference Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS (2011) Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 16:1589–1599PubMedCentralPubMedCrossRef Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS (2011) Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 16:1589–1599PubMedCentralPubMedCrossRef
9.
go back to reference Chan CC, Sen HN (2013) Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med 15:93–100PubMedCentralPubMed Chan CC, Sen HN (2013) Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med 15:93–100PubMedCentralPubMed
10.
go back to reference Sierra Del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xuan K (2009) Primary CNS lymphoma in immunocompetent patients. Oncologist 14:526–539PubMedCrossRef Sierra Del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xuan K (2009) Primary CNS lymphoma in immunocompetent patients. Oncologist 14:526–539PubMedCrossRef
11.
go back to reference Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA (1997) Intravitreal methotrexate as an adjunctive treatment of ocular lymphoma. Arch Ophthalmol 115:1152–1156PubMedCrossRef Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA (1997) Intravitreal methotrexate as an adjunctive treatment of ocular lymphoma. Arch Ophthalmol 115:1152–1156PubMedCrossRef
12.
go back to reference de Smet MD, Vancs VS, Kohler D, Solomon D, Chan CC (1999) Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 83:448–451PubMedCentralPubMedCrossRef de Smet MD, Vancs VS, Kohler D, Solomon D, Chan CC (1999) Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 83:448–451PubMedCentralPubMedCrossRef
13.
go back to reference Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe'er J (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709–1716PubMedCrossRef Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe'er J (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109:1709–1716PubMedCrossRef
14.
go back to reference Kitzmann AS, Pulido JS, Mohney BG, Baratz KH, Grube T, Marler RJ, Donaldson MJ, O'Neill BP, Johnston PB, Johnson KM, Dixon LE, Salomao DR, Cameron JD (2007) Intraocular use of rituximab. Eye (Lond) 21:1524–1527CrossRef Kitzmann AS, Pulido JS, Mohney BG, Baratz KH, Grube T, Marler RJ, Donaldson MJ, O'Neill BP, Johnston PB, Johnson KM, Dixon LE, Salomao DR, Cameron JD (2007) Intraocular use of rituximab. Eye (Lond) 21:1524–1527CrossRef
15.
go back to reference Ohguro N, Hashida N, Tano Y (2008) Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 126:1002–1003PubMedCrossRef Ohguro N, Hashida N, Tano Y (2008) Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 126:1002–1003PubMedCrossRef
16.
go back to reference Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574PubMedCrossRef Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574PubMedCrossRef
17.
go back to reference Hill QA, Owen RG (2006) CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 20:319–332PubMedCrossRef Hill QA, Owen RG (2006) CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 20:319–332PubMedCrossRef
18.
go back to reference Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y (2002) Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 95:576–580PubMedCrossRef Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y (2002) Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 95:576–580PubMedCrossRef
19.
go back to reference Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036–1047PubMedCrossRef Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036–1047PubMedCrossRef
20.
go back to reference Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquières H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A, Houillier C, Taillandier L, Hoang-Xuan K, Leblond V (2012) Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: A retrospective study of 79 cases. Haematologica 97:1751–1756PubMedCentralPubMedCrossRef Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquières H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A, Houillier C, Taillandier L, Hoang-Xuan K, Leblond V (2012) Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: A retrospective study of 79 cases. Haematologica 97:1751–1756PubMedCentralPubMedCrossRef
21.
go back to reference Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859–863PubMed Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859–863PubMed
22.
go back to reference Kiewe P, Fischer L, Martus P, Thiel E, Korfel A (2010) Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro Oncol 12:409–417PubMedCentralPubMedCrossRef Kiewe P, Fischer L, Martus P, Thiel E, Korfel A (2010) Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro Oncol 12:409–417PubMedCentralPubMedCrossRef
23.
go back to reference Freeman LN, Schachat AP, Knox DL, Michels RG, Green WR (1987) Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology 94:1631–1639PubMedCrossRef Freeman LN, Schachat AP, Knox DL, Michels RG, Green WR (1987) Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology 94:1631–1639PubMedCrossRef
24.
go back to reference Char DH, Ljung BM, Miller T, Phillips T (1988) Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 95:625–630PubMedCrossRef Char DH, Ljung BM, Miller T, Phillips T (1988) Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 95:625–630PubMedCrossRef
25.
go back to reference Siegel MJ, Dalton J, Friedman AH, Strauchen J, Watson C (1989) Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma). Br J Ophthalmol 73:342–346PubMedCentralPubMedCrossRef Siegel MJ, Dalton J, Friedman AH, Strauchen J, Watson C (1989) Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma). Br J Ophthalmol 73:342–346PubMedCentralPubMedCrossRef
26.
go back to reference Buggage RR, Chan CC, Nussenblatt RB (2001) Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 13:137–142PubMedCrossRef Buggage RR, Chan CC, Nussenblatt RB (2001) Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 13:137–142PubMedCrossRef
27.
go back to reference Ferreri AJ, Blay JY, Reni M, Pasini F, Gubkin A, Tirelli U, Calderoni A, Zucca E, Cortelazzo S, Chassagne C, Tinguely M, Borisch B, Berger F, Ponzoni M, Cavalli F, International Extranodal Lymphoma Study Group (IELSG) (2002) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13:531–538PubMedCrossRef Ferreri AJ, Blay JY, Reni M, Pasini F, Gubkin A, Tirelli U, Calderoni A, Zucca E, Cortelazzo S, Chassagne C, Tinguely M, Borisch B, Berger F, Ponzoni M, Cavalli F, International Extranodal Lymphoma Study Group (IELSG) (2002) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13:531–538PubMedCrossRef
28.
go back to reference Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, Coupland SE (2006) Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 244:663–669PubMedCrossRef Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, Coupland SE (2006) Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 244:663–669PubMedCrossRef
29.
go back to reference Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9:711–715PubMed Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9:711–715PubMed
30.
go back to reference Vosganian GS, Boisot S, Hartmann KI, Freeman WR, Sharpe RW, Tripuraneni P, Saven A (2011) Primary intraocular lymphoma: a review. J Neurooncol 105:127–134PubMedCrossRef Vosganian GS, Boisot S, Hartmann KI, Freeman WR, Sharpe RW, Tripuraneni P, Saven A (2011) Primary intraocular lymphoma: a review. J Neurooncol 105:127–134PubMedCrossRef
31.
Metadata
Title
Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma
Authors
Noriyasu Hashida
Kei Nakai
Norimitsu Saitoh
Kohji Nishida
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 4/2014
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-014-2584-8

Other articles of this Issue 4/2014

Graefe's Archive for Clinical and Experimental Ophthalmology 4/2014 Go to the issue